Statin-Fenofibrate Co-Initiation Linked to Lower Dialysis Risk in CKD Cohort

Among adults with non-dialysis-dependent chronic kidney disease (CKD), ischemic heart disease (IHD), and hypertriglyceridemia, starting fenofibrate within 3 months of statin initiation was associated with lower risks of major adverse cardiovascular events (MACE) and end-stage kidney disease (ESKD) necessitating dialysis compared with statin monotherapy, according to a retrospective cohort study published in the Clinical Kidney Journal.

The authors noted that safety concerns, including myopathy and rhabdomyolysis with statin-fenofibrate combination therapy, have led to cautious fenofibrate use in CKD, and that the Kidney Disease: Improving Global Outcomes (KDIGO) lipid guideline recommends avoiding concomitant fibrate and statin use in patients with CKD.

Investigators emulated a target trial using TriNetX Global Collaborative Network data from 105 healthcare organizations between 2018 and 2024. After propensity score matching, each group included 3,191 patients. MACE was defined as acute myocardial infarction, stroke, heart failure, cardiac arrest, or all-cause death. It occurred in 46.1% of the combination-therapy group vs 49.4% of the statin-monotherapy group (hazard ratio [HR], 0.93; 95% CI, 0.86-0.99). Over 4 years, ESKD necessitating dialysis occurred in 8.3% vs 10.5% of patients, respectively (average HR, 0.79; 95% CI, 0.67-0.92).

All-cause mortality and acute kidney injury did not differ significantly between groups. In a separate matched analysis, rhabdomyolysis, myopathy, and impaired liver function were not significantly more frequent with combination therapy. The investigators described the cardiovascular association as modest and less consistent across propensity score specifications. The renal association was consistent across sensitivity analyses.

The authors reported several limitations: residual confounding, including confounding by indication; exposure based on prescription records without adherence or dose information; and CKD defined by a single estimated glomerular filtration rate measurement. They cautioned against extrapolating the findings to dialysis populations, transplant recipients, or patients with advanced CKD in whom fenofibrate is contraindicated. They also said prospective trials are warranted to establish whether fenofibrate slows progression to kidney failure in this population.

Source: Chang YC, Tsai MH, Fang YW, Chen MT, Tseng YH, Wei CC. Combined statin and fenofibrate therapy and cardiorenal outcomes in patients with CKD, dyslipidemia, and ischemic heart disease. Clin Kidney J. Published online October 1, 2026. doi:10.1093/ckj/sfag343